Skip to main content
Erschienen in: Wiener klinische Wochenschrift 17-18/2023

07.03.2023 | original article

Primary tumor SUVmax and ratio of SUVmax to primary tumor size on pretreatment 18F-FDG-PET/CT scan in small cell lung cancer

Which is superior for the prognosis?

verfasst von: Dr. Faruk Tas, Akın Ozturk, Kayhan Erturk

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 17-18/2023

Einloggen, um Zugang zu erhalten

Summary

Background

The prognostic impact of tumor SUVmax (t-SUVmax) in small cell lung cancer (SCLC) has been questioned with controversial results, and the significance of the ratio of tumor SUVmax to primary tumor size (SUVmax/t-size) in SCLC has yet to be clarified as well. In this study, a retrospective analysis was carried out to figure out the prognostic and predictive powers of pretreatment primary t‑SUVmax and t‑SUVmax/t-size ratio in patients with SCLC.

Methods

A total of 349 SCLC patients who underwent pretreatment staging with PET/CT scan were enrolled in the study and analyzed retrospectively.

Results

In limited disease SCLC (LD-SCLC), tumor size was significantly associated with both t‑SUVmax (p = 0.02) and t‑SUVmax/t-size (p = 0.0001). Furthermore, performance status, tumor size (p = 0.001), and liver metastasis were significantly associated with t‑SUVmax in extended disease SCLC (ED-SCLC). Moreover, tumor size (p = 0.0001), performance status, cigarette smoking history, and pulmonary/pleural metastasis were found to be correlated with t‑SUVmax/t-size. No associations were found between clinical stages and either t‑SUVmax or t‑SUVmax/t-size (p = 0.9 for both), and t‑SUVmax and t‑SUVmax/t-size values were found to have similar survival rates in both LD-SCLC and ED-SCLC patients. In univariate and multivariate analyses, both t‑SUVmax and t‑SUVmax/t-size were found not to be associated with overall survival (p > 0.05)

Conclusion

This study does not advocate the use of either t‑SUVmax or t‑SUVmax/t-size on pretreatment 18F‑FDG-PET/CT scan as prognostic and predictive tools for both LD-SCLC and ED-SCLC patients. Likewise, we did not find that t‑SUVmax/t-size was superior to t‑SUVmax in that respect.
Literatur
1.
Zurück zum Zitat Martucci F, Pascale M, Valli MC, Pesce GA, Froesch P, Giovanella L, et al. Impact of 18F-FDG PET/CT in staging patients with small cell lung cancer: a systematic review and meta-analysis. Front Med. 2020;6:336.CrossRef Martucci F, Pascale M, Valli MC, Pesce GA, Froesch P, Giovanella L, et al. Impact of 18F-FDG PET/CT in staging patients with small cell lung cancer: a systematic review and meta-analysis. Front Med. 2020;6:336.CrossRef
2.
Zurück zum Zitat Choi EK, Park M, Im JJ, Chung YA, Oh JK. Prognostic value of (18)F-FDG PET/CT metabolic parameters in small cell lung cancer. J Int Med Res. 2020;48(4):300060519892419.CrossRefPubMed Choi EK, Park M, Im JJ, Chung YA, Oh JK. Prognostic value of (18)F-FDG PET/CT metabolic parameters in small cell lung cancer. J Int Med Res. 2020;48(4):300060519892419.CrossRefPubMed
3.
Zurück zum Zitat Lin X, Xiao Z, Hu Y, Zhang X, Fan W. Combining 18F-FDG PET/CT and serum lactate dehydrogenase for prognostic evaluation of small cell lung cancer. Front Pharmacol. 2020;11:592768.CrossRefPubMedPubMedCentral Lin X, Xiao Z, Hu Y, Zhang X, Fan W. Combining 18F-FDG PET/CT and serum lactate dehydrogenase for prognostic evaluation of small cell lung cancer. Front Pharmacol. 2020;11:592768.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Inal A, Kucukoner M, Kaplana MA, Urakcı Z, Nas N, Guven M, Dostbil Z, Altındag S, Isıkdogan A. Is 18F-FDG-PET/CT prognostic factor for survival in patients with small cell lung cancer? Single center experience. Rev Port Pneumol. 2013;19:260–5.CrossRefPubMed Inal A, Kucukoner M, Kaplana MA, Urakcı Z, Nas N, Guven M, Dostbil Z, Altındag S, Isıkdogan A. Is 18F-FDG-PET/CT prognostic factor for survival in patients with small cell lung cancer? Single center experience. Rev Port Pneumol. 2013;19:260–5.CrossRefPubMed
5.
Zurück zum Zitat Kim SJ, Chang S. Limited prognostic value of SUVmax measured by F‑18 FDG PET/CT in newly diagnosed small cell lung cancer patients. Oncol Res Treat. 2015;38:577–85.CrossRefPubMed Kim SJ, Chang S. Limited prognostic value of SUVmax measured by F‑18 FDG PET/CT in newly diagnosed small cell lung cancer patients. Oncol Res Treat. 2015;38:577–85.CrossRefPubMed
6.
Zurück zum Zitat Christensen TN, Andersen PK, Langer SW, Fischer BMB. Prognostic value of 18F–FDG–PET parameters in patients with small cell lung cancer: a meta-analysis and review of current literature. Diagnostics. 2021;11:174.CrossRefPubMedPubMedCentral Christensen TN, Andersen PK, Langer SW, Fischer BMB. Prognostic value of 18F–FDG–PET parameters in patients with small cell lung cancer: a meta-analysis and review of current literature. Diagnostics. 2021;11:174.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Stiles BM, Nasar A, Mirza F, et al. Ratio of positron emission tomography uptake to tumor size in surgically resected non-small cell lung cancer. Ann Thorac Surg. 2013;95:397–403.CrossRefPubMed Stiles BM, Nasar A, Mirza F, et al. Ratio of positron emission tomography uptake to tumor size in surgically resected non-small cell lung cancer. Ann Thorac Surg. 2013;95:397–403.CrossRefPubMed
8.
Zurück zum Zitat Chen F, Yao Y, Ma C, Ma X, Wang Z, Lv T, Xiao X, Yin J, Song Y. Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res. 2015;4:18–26.PubMedPubMedCentral Chen F, Yao Y, Ma C, Ma X, Wang Z, Lv T, Xiao X, Yin J, Song Y. Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res. 2015;4:18–26.PubMedPubMedCentral
9.
Zurück zum Zitat Kasahara N, Kaira K, Yamaguchi K, Masubuchi H, Tsurumaki H, Hara K, Koga Y, Sakurai R, Higuchi T, Handa T, et al. Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer. Lung Cancer. 2019;134:180–6.CrossRefPubMed Kasahara N, Kaira K, Yamaguchi K, Masubuchi H, Tsurumaki H, Hara K, Koga Y, Sakurai R, Higuchi T, Handa T, et al. Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer. Lung Cancer. 2019;134:180–6.CrossRefPubMed
10.
Zurück zum Zitat Aktan M, Koc M, Kanyilmaz G, Yavuz BB. Prognostic value of pre-treatment (18)F-FDG-PET uptake in small-cell lung cancer. Ann Nucl Med. 2017;31:462–8.CrossRefPubMed Aktan M, Koc M, Kanyilmaz G, Yavuz BB. Prognostic value of pre-treatment (18)F-FDG-PET uptake in small-cell lung cancer. Ann Nucl Med. 2017;31:462–8.CrossRefPubMed
11.
Zurück zum Zitat Kwon SH, Hyun SH, Yoon JK, An YS, Oh YT, Choi JH, Park KJ, Lee SJ. The highest metabolic activity on FDG PET is associated with overall survival in limited-stage small-cell lung cancer. Medicine. 2016;95:e2772.CrossRefPubMedPubMedCentral Kwon SH, Hyun SH, Yoon JK, An YS, Oh YT, Choi JH, Park KJ, Lee SJ. The highest metabolic activity on FDG PET is associated with overall survival in limited-stage small-cell lung cancer. Medicine. 2016;95:e2772.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat van der Leest C, Smit EF, Baas J, Versteijlen RJ, van Walree N, Hoogsteden HC, Aerts JG. SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer? Lung Cancer. 2012;76:67–71.CrossRefPubMed van der Leest C, Smit EF, Baas J, Versteijlen RJ, van Walree N, Hoogsteden HC, Aerts JG. SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer? Lung Cancer. 2012;76:67–71.CrossRefPubMed
13.
Zurück zum Zitat Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011;73:332–7.CrossRefPubMed Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011;73:332–7.CrossRefPubMed
14.
Zurück zum Zitat Chong S, Lee KS, Kim BT, Choi JY, Yi CA, Chung MJ, Oh DK, Lee JY. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol. 2007;188:1223–31.CrossRefPubMed Chong S, Lee KS, Kim BT, Choi JY, Yi CA, Chung MJ, Oh DK, Lee JY. Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol. 2007;188:1223–31.CrossRefPubMed
15.
Zurück zum Zitat Ozdemir O, Batum O, Ermin S, Aksel N, Komurcuoglu B, Mertoglu A, Deniz S, Balci G, Koparal H, Ozbilek E, et al. Metabolic activity of primary tumour on PET/CT has a relationship with survival in stages I‑III small-cell lung carcinoma. Clin Respir J. 2020; https://doi.org/10.1111/crj.13186.CrossRefPubMed Ozdemir O, Batum O, Ermin S, Aksel N, Komurcuoglu B, Mertoglu A, Deniz S, Balci G, Koparal H, Ozbilek E, et al. Metabolic activity of primary tumour on PET/CT has a relationship with survival in stages I‑III small-cell lung carcinoma. Clin Respir J. 2020; https://​doi.​org/​10.​1111/​crj.​13186.CrossRefPubMed
16.
Zurück zum Zitat Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, Bom HS. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:925–35.CrossRefPubMed Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, Bom HS. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39:925–35.CrossRefPubMed
17.
Zurück zum Zitat Nobashi T, Koyasu S, Nakamoto Y, Kubo T, Ishimori T, Kim YH, Yoshizawa A, Togashi K. Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer. Br J Radiol. 2016;89:20150618.CrossRefPubMedPubMedCentral Nobashi T, Koyasu S, Nakamoto Y, Kubo T, Ishimori T, Kim YH, Yoshizawa A, Togashi K. Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer. Br J Radiol. 2016;89:20150618.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Zer A, Domachevsky L, Rapson Y, Nidam M, Flex D, Allen AM, Stemmer SM, Groshar D, Bernstine H. The role of 18F-FDG PET/CT on staging and prognosis in patients with small cell lung cancer. Eur Radiol. 2016;26:3155–61.CrossRefPubMed Zer A, Domachevsky L, Rapson Y, Nidam M, Flex D, Allen AM, Stemmer SM, Groshar D, Bernstine H. The role of 18F-FDG PET/CT on staging and prognosis in patients with small cell lung cancer. Eur Radiol. 2016;26:3155–61.CrossRefPubMed
20.
Zurück zum Zitat Cheng G, Huang H. Prognostic value of (18)F-fluorodeoxyglucose PET/computed tomography in non-small-cell lung cancer. PET Clin. 2018;13:59–72.CrossRefPubMed Cheng G, Huang H. Prognostic value of (18)F-fluorodeoxyglucose PET/computed tomography in non-small-cell lung cancer. PET Clin. 2018;13:59–72.CrossRefPubMed
21.
Zurück zum Zitat Lee HY, Hyun SH, Lee KS, et al. Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2010;17:2787–94.CrossRefPubMed Lee HY, Hyun SH, Lee KS, et al. Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2010;17:2787–94.CrossRefPubMed
Metadaten
Titel
Primary tumor SUVmax and ratio of SUVmax to primary tumor size on pretreatment 18F-FDG-PET/CT scan in small cell lung cancer
Which is superior for the prognosis?
verfasst von
Dr. Faruk Tas
Akın Ozturk
Kayhan Erturk
Publikationsdatum
07.03.2023
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 17-18/2023
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-023-02160-0

Weitere Artikel der Ausgabe 17-18/2023

Wiener klinische Wochenschrift 17-18/2023 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Billrothhaus: 130 Jahre Schauplatz der Medizingeschichte

MUW researcher of the month

MUW researcher of the month